CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2005; 55:300-318
doi: 10.3322/canjclin.55.5.300
© 2005 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 Advances in Prostate Cancer Chemotherapy: A New Era Begins
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pienta, K. J.
Right arrow Articles by Smith, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pienta, K. J.
Right arrow Articles by Smith, D. C.

Advances in Prostate Cancer Chemotherapy: A New Era Begins1

Kenneth J. Pienta, MD2 and David C. Smith, MD


Dr. Pienta is Professor of Medicine and Urology, American Cancer Society Clinical Research Professor, Michigan Urology Center, University of Michigan, Ann Arbor, MI.
Dr. Smith is Director, Multidisciplinary Urologic Oncology Clinic, Associate Professor of Medicine and Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

Prostate cancer continues to be the most common lethal malignancy diagnosed in American men and the second leading cause of male cancer mortality. Over 60 years ago, Huggins and Hodges discovered androgen deprivation as a first-line therapy for metastatic prostate cancer, which leads to remissions typically lasting 2 to 3 years, but in most men prostate cancer ultimately progresses to an androgen-independent state resulting in death due to widespread metastases. Multiple mechanisms of androgen independence have now been documented, including amplification of the androgen receptor as well as signal transduction pathways that bypass the androgen receptor completely. In 2004, two landmark studies demonstrated a survival advantage in androgen-independent prostate cancer patients utilizing docetaxel chemotherapy, setting a new standard of care for this disease. In addition, treatments with the bisphosphonate zoledronic acid and systemic radioisotopes have also been shown to have palliative benefits in this population. Building on these advances, several new traditional chemotherapeutic agents as well as new targeted therapies are under development.




This article has been cited by other articles:


Home page
 cfpHome page
A. N. Wilkinson, M. D. Brundage, and R. Siemens
Approach to primary care follow-up of patients with prostate cancer
Can Fam Physician, February 1, 2008; 54(2): 204 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Fizazi
The role of Src in prostate cancer
Ann. Onc., November 1, 2007; 18(11): 1765 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Oudard, E. Banu, F. Scotte, A. Banu, J. Medioni, P. Beuzeboc, F. Joly, J.-M. Ferrero, F. Goldwasser, and J.-M. Andrieu
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
Ann. Onc., November 1, 2007; 18(11): 1828 - 1833.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Buchanan, C. Ricciardelli, J. M. Harris, J. Prescott, Z. C.-L. Yu, L. Jia, L. M. Butler, V. R. Marshall, H. I. Scher, W. L. Gerald, et al.
Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamine Rich Tetratricopeptide Repeat Containing Protein {alpha}
Cancer Res., October 15, 2007; 67(20): 10087 - 10096.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J-C Eymard, F Priou, A Zannetti, A Ravaud, D Lepille, P Kerbrat, P Gomez, B Paule, D Genet, P Herait, et al.
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
Ann. Onc., June 1, 2007; 18(6): 1064 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. S. Zorn, K. J. Wojno, M. T. McCabe, R. Kuefer, J. E. Gschwend, and M. L. Day
5-Aza-2'-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2136 - 2143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Vessella and E. Corey
Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. L. Kovar, M. A. Johnson, W. M. Volcheck, J. Chen, and M. A. Simpson
Hyaluronidase Expression Induces Prostate Tumor Metastasis in an Orthotopic Mouse Model
Am. J. Pathol., October 1, 2006; 169(4): 1415 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. E. Garcia, H.-G. Wisniewski, M. S. Lucia, N. Arevalo, T. J. Slaga, S. L. Kraft, R. Strange, and A. P. Kumar
2-Methoxyestradiol Inhibits Prostate Tumor Development in Transgenic Adenocarcinoma of Mouse Prostate: Role of Tumor Necrosis Factor-{alpha}-Stimulated Gene 6
Clin. Cancer Res., February 1, 2006; 12(3): 980 - 988.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by American Cancer Society.